Phase II trial of the phosphatidyinositol-3 kinase (PLIK) inhibitor buparlisib (BKM120) in recurrent glioblastoma

被引：4
|
作者：
Wen, Patrick Y.
Yung, W. K. Alfred
Mellinghoff, Ingo K.
Ramkissoon, Shakti
Alexander, Brian Michael
Rinne, Mikael L.
Colman, Howard
Omura, Antonio MarcIllo Paduia
DeAngelis, Lisa Marie
Gilbert, Mark R.
De Groot, John Frederick
Cloughesy, Timothy Francis
Chi, Andrew S.
Lee, Eudocia Quant
Nayak, Lakshmi
Batchelor, Tracy
Chang, Susan Marina
Prados, Michael
Reardon, David A.
Ligon, Keith L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2019
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial
    Fayette, J.
    Digue, L.
    Segura-Ferlay, C.
    Treilleux, I.
    Wang, Q.
    Lefebvre, G.
    Daste, A.
    Even, C.
    Thaunat, S. Couchon
    Guyennon, A.
    Peyrade, F.
    Cupissol, D.
    You, B.
    Le Tourneau, C.
    Jaouen, L.
    Grinand, E.
    Tabone-Eglinger, S.
    Garin, G.
    Perol, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 455 - 455
  • [12] Discovery of BKM120, a pan class I PI3 kinase inhibitor in phase I/II clinical trials
    Burger, Matthew T.
    Pecchi, Sabina
    Wagman, Allan
    Ni, Zhi-Jie
    Knapp, Mark
    Atallah, Gordana
    Pfister, Keith
    Ng, Simon
    Smith, Aaron
    Pick, Teresa
    Frazier, Kelly
    Verhagen, Joelle
    Zhang, Yanchen
    Bartulis, Sarah
    Hendricksen, Tom
    Iwanowicz, Edwin
    Hazenadar, Joshua
    Huh, Kay
    Ashash, Ahmad
    Xin, Xiaohua
    Menezes, Daniel
    Merritt, Hanne
    Wiesmann, Marion
    Voliva, Charles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [13] Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
    Armstrong, Andrew J.
    Halabi, Susan
    Healy, Patrick
    Alumkal, Joshi J.
    Winters, Carolyn
    Kephart, Julie
    Bitting, Rhonda L.
    Hobbs, Carey
    Soleau, Colleen F.
    Beer, Tomasz M.
    Slottke, Rachel
    Mundy, Kelly
    Yu, Evan Y.
    George, Daniel J.
    EUROPEAN JOURNAL OF CANCER, 2017, 81 : 228 - 236
  • [14] Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).
    Armstrong, Andrew J.
    Halabi, Susan
    Healy, Patrick
    Alumkal, Joshi J.
    Yu, Evan Y.
    Winters, Carolyn
    Hobbs, Carey
    Soleau, Colleen
    Slottke, Rachel
    Mundy, Kelly
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [15] Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics
    Azaro, A.
    Rodon, J.
    Vansteenkiste, J. F.
    Ando, Y.
    Doi, T.
    Mills, D.
    Sarr, C.
    Di Tomaso, E.
    Massacesi, C.
    Naumann, R. W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S186 - S186
  • [16] Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
    Hainsworth, John D.
    Becker, Kevin P.
    Mekhail, Tarek
    Chowdhary, Sajeel A.
    Eakle, Janice Faulkner
    Wright, David
    Langdon, Robert M.
    Yost, Kathleen J.
    Padula, Gilbert Darin Anthony
    West-Osterfield, Kimberly
    Scarberry, Meredith
    Shaifer, Candice A.
    Shastry, Mythili
    Burris, Howard A., III
    Shih, Kent
    JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 303 - 311
  • [17] A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Schram, A. M.
    Dickler, M. N.
    BREAST DISEASES, 2016, 27 (04): : 315 - 318
  • [18] Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
    John D. Hainsworth
    Kevin P. Becker
    Tarek Mekhail
    Sajeel A. Chowdhary
    Janice Faulkner Eakle
    David Wright
    Robert M. Langdon
    Kathleen J. Yost
    Gilbert Darin Anthony Padula
    Kimberly West-Osterfield
    Meredith Scarberry
    Candice A. Shaifer
    Mythili Shastry
    Howard A. Burris
    Kent Shih
    Journal of Neuro-Oncology, 2019, 144 : 303 - 311
  • [19] Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
    Geisthoff, Urban W.
    Nguyen, Ha-Long P.
    Hess, Dagmar
    ANNALS OF HEMATOLOGY, 2014, 93 (04) : 703 - 704
  • [20] Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120
    Urban W. Geisthoff
    Ha-Long P. Nguyen
    Dagmar Hess
    Annals of Hematology, 2014, 93 : 703 - 704
12345